An open-label, phase 2 study evaluating the efficacy and safety of the anti-IGF-1R antibody cixutumumab in patients with previously treated advanced or metastatic soft-tissue sarcoma or Ewing family of tumours
Schöffski, P, Adkins, D, Blay, J.-Y, Gil, T, Elias, A.D, Rutkowski, P, Pennock, G.K, Youssoufian, H, Gelderblom, H, Willey, R, Grebennik, D.O
Published in European journal of cancer (1990) (01.10.2013)
Published in European journal of cancer (1990) (01.10.2013)
Get full text
Journal Article